Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002995 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 483
- Enrollment target
NCT00002995 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 483 participants.
The verdict
NCT00002995, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 483 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether chemotherapy is more effective with or without radiation therapy in treating patients who have rhabdomyosarcoma. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy in treating patients who have newly-diagnosed rhabdomyosarcoma.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- BIOLOGICAL sargramostim
- BIOLOGICAL dactinomycin
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 483 participants |
| Start Date | 1997-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002995
The ClinicalTrials.gov registry entry for NCT00002995 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 483 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002995 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002995 about?
NCT00002995 is a clinical study titled "Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether chemotherapy is more effective with or without radiation therapy in treating patien...
What is the current status of trial NCT00002995?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 483 participants. The study started on 1997-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00002995?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), sargramostim (BIOLOGICAL), dactinomycin (BIOLOGICAL), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00002995?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.